Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis

Assessment report Addendum (PDF 155 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: review consultation - May 2015 information

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: appendix A -matrix of stakeholders (PDF 98 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: appendix B -GE Proposal Paper May 2015 (PDF 454 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: equality impact assessment - guidance development (PDF 83 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: final appraisal determination information

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: final appraisal determination document (PDF 555 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) (PDF 558 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: consultee and commentator comments on the ACD

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Novartis comments (PDF 251 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Cystic Fibrosis Trust comments (PDF 120 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Chartered Society of Physiotherapy comments (PDF 191 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Royal College of Nursing comments (PDF 174 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Royal College of Paediatrics and Child Health comments (PDF 90 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Healthcare Improvement Scotland comments (PDF 96 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Expert comments on the ACD

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Professor Andrew Greening (clinical specialist) nominated by Healthcare Improvement Scotland (PDF 252 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Dr Robert Ian Ketchell (clinical specialist) nominated by Forest Laboratories UK (PDF 174 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Emma Lake and Nikki Samsa (patient experts) nominated by the Cystic Fibrosis Trust - joint submission (PDF 41 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Comments on the ACD received from the public through the NICE website

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Comments on the ACD Received from the Public through the NICE Website (PDF 222 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Additional public comment received via email (reference article not included) (PDF 103 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: additional evidence

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Updated Patient Access Scheme (PAS) submission from Forest Laboratories UK (PDF 812 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Economic analysis of updated Patient Access Scheme prepared by School of Health and Related Research (ScHARR) (PDF 147 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Summary of non-inferiority analysis in updated Patient Access Scheme prepared by School of Health and Related Research (ScHARR) (PDF 319 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: appraisal consultation

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: appraisal consultation document information

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: evaluation report

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: overview (PDF 455 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: assessment report addendum - Novartis PAS analysis (PDF 211 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: consultee and commentator comments on the assessment report

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Forest Laboratories UK (PDF 206 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Novartis (PDF 451 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: British Thoracic Society (endorsed by Royal College of Physicians) (PDF 73 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Chartered Society of Physiotherapy (PDF 81 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Royal College of Paediatrics and Child Health (PDF 73 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Healthcare Improvement Scotland (PDF 71 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: response to consultee and commentator comments on the assessment report (PDF 163 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: manufacturer submissions (executive summary only)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Forest Laboratories UK Executive Summary (PDF 55 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Novartis Executive Summary (PDF 208 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Novartis PAS submission (PDF 182 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: non-manufacturer submission

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: British Thoracic Society (endorsed by Royal College of Physicians) (PDF 184 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Royal College of Nursing (PDF 46 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Royal College of Paediatricians and Child Health (PDF 50 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: expert written personal statements

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Greening (PDF 61 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Ketchell (PDF 111 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Lake (PDF 100 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Samsa (PDF 62 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: additional information - personal perspectives from experts who could not attend the first committee meeting on the rescheduled date

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Hull (PDF 53 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Morton (PDF 97 KB)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin [ID342]: assessment report (PDF 2.7 MB)

Cystic fibrosis (pseudomonas lung infection) colistimethate powder and tobramycin powder: scoping Equality Impact Assessment form (PDF 47 KB)

Cystic fibrosis (pseudomonas lung infection) colistimethate powder and tobramycin powder: final protocol (PDF 121 KB)

Cystic fibrosis (pseudomonas lung infection) colistimethate powder and tobramycin powder: final scope (PDF 47 KB)

Cystic fibrosis (pseudomonas lung infection) colistimethate powder and tobramycin powder: final matrix (PDF 43 KB)

Cystic fibrosis (pseudomonas lung infection) colistimethate powder and tobramycin powder: response to consultee and commentator comments on draft scope (PDF 182 KB)

Cystic fibrosis (pseudomonas lung infection) colistimethate powder and tobramycin powder: response to consultee and commentator comments on provisional matrix (PDF 36 KB)

Cystic fibrosis (Pseudomonas aeruginosa lung infection) - colistimethate sodium: draft scope for consultation (pre-referral) (PDF 31 KB)

Cystic fibrosis (Pseudomonas aeruginosa lung infection) - colistimethate sodium: provisional matrix (pre-referral) (PDF 30 KB)

Cystic fibrosis (Pseudomonas aeruginosa lung infection) - colistimethate sodium: draft scope for consultation (pre-referral) (PDF 31 KB)

Cystic fibrosis (Pseudomonas aeruginosa lung infection) - colistimethate sodium: provisional matrix (pre-referral) (PDF 30 KB)